Cardiff Oncology, Inc. (CRDF)

NASDAQ: CRDF · IEX Real-Time Price · USD
1.780
+0.070 (4.09%)
Feb 27, 2024, 4:00 PM EST - Market closed
4.09%
Market Cap 78.19M
Revenue (ttm) 460,000
Net Income (ttm) -40.83M
Shares Out 44.68M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 165,604
Open 1.740
Previous Close 1.710
Day's Range 1.720 - 1.835
52-Week Range 0.940 - 2.790
Beta 1.68
Analysts Strong Buy
Price Target 12.00 (+574.16%)
Earnings Date Feb 29, 2024

About CRDF

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serve... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 25
Stock Exchange NASDAQ
Ticker Symbol CRDF
Full Company Profile

Financial Performance

In 2022, CRDF's revenue was $386,000, an increase of 7.52% compared to the previous year's $359,000. Losses were -$38.73 million, 36.8% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for CRDF stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target
$12.0
(574.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...

1 day ago - GlobeNewsWire

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m.

5 days ago - GlobeNewsWire

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

- Findings from the Phase 1b portion of company's Phase 1b/2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with standard-of-care - - ...

5 weeks ago - PRNewsWire

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

SAN DIEGO , Nov. 20, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

3 months ago - PRNewsWire

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

- Advance to first-line RAS-mutated metastatic colorectal cancer (mCRC) for lead program based on positive clinical and preclinical data and guidance from FDA -  - Expanded relationship with Pfizer, w...

4 months ago - PRNewsWire

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

- Management will hold a conference call on Thursday, November 2 at 4:30 p.m. ET/1:30 p.m.

4 months ago - PRNewsWire

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

Cardiff Oncology Inc. CRDF, +0.62% shares surged 32% on favorable data from two cancer drug trials — metastatic pancreatic ductal adenocarcinoma and small cell lung cancer treatment.

Other symbols: COSTMLKNMORFPRGSTRUE
5 months ago - Market Watch

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% (vs.

5 months ago - PRNewsWire

Cardiff Oncology to Present at Upcoming Investor Conferences in September

SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop no...

6 months ago - PRNewsWire

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

- New lead program in first-line RAS-mutated metastatic colorectal cancer (mCRC) and expanded Pfizer relationship; interim topline data expected in mid-2024 - - Advance to first-line mCRC follows stro...

7 months ago - PRNewsWire

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

- Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA -  - First-line mCRC represents substantial increase in patient impact...

7 months ago - PRNewsWire

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , July 24, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop no...

7 months ago - PRNewsWire

Cardiff Oncology to Present at the Jefferies Healthcare Conference

SAN DIEGO , June 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop nov...

9 months ago - PRNewsWire

Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full membership of Scientific Advisory Board (...

10 months ago - PRNewsWire

Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer

SAN DIEGO , March 28, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop n...

1 year ago - PRNewsWire

Cardiff Oncology Formally Introduces Scientific Advisory Board

- SAB includes recognized leaders with expertise in oncology drug development, pharmaceutical industry dynamics and translational research – - SAB will continue to provide insight and guidance on the ...

1 year ago - PRNewsWire

Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective response rate, durability and progression-f...

1 year ago - PRNewsWire

Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference

SAN DIEGO , Feb. 27, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop no...

1 year ago - PRNewsWire

Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer

Brings world class capabilities and deep expertise in colorectal cancer and other solid tumor indications to advance the clinical development of onvansertib  Served as the lead investigator for two pr...

1 year ago - PRNewsWire

Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference

SAN DIEGO , Jan. 10, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

1 year ago - PRNewsWire

Cardiff Oncology to Present at Upcoming Investor Conferences

SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

1 year ago - PRNewsWire

Cardiff Oncology to Present at the Jefferies London Healthcare Conference

SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, ...

1 year ago - PRNewsWire

Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates

Data from Phase 1b/2 trial in KRAS-mutated metastatic colorectal cancer (mCRC), per September 12 th announcement, show durable responses to treatment and support initiation of ONSEMBLE, a randomized P...

1 year ago - PRNewsWire

Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates

Next trial in RAS-mutated mCRC (ONSEMBLE) is a randomized Phase 2 trial to demonstrate onvansertib's contribution to SoC and position for a possible accelerated approval opportunity; topline data expe...

1 year ago - PRNewsWire

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022

Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC...

1 year ago - PRNewsWire